Supplementary Table 1. Baseline characteristics of patients who underwent routine primary TKA in 2019.

Baseline characteristic	No albumin	Albumin use	All	
	(n = 563)	(n = 97)	(n=660)	
Demographic characteristic				
Age (years)	67.33±8.55	69.44±7.86	67.64±8.48	
Female	447 (79.4)	79 (81.4)	526 (79.7)	
BMI (kg/m^2)	25.90±3.53	25.50±4.00	25.84±3.60	
Diagnosis				
Primary osteoarthritis	529 (95.0)	85 (87.6)	614 (93.0)	
Inflammatory arthritis	34 (6.04)	12 (12.3)	46 (6.97)	
Comorbidity				
Hypertension	250 (44.4)	35 (36.1)	285 (43.2)	
Diabetes	66 (11.7)	11 (11.3)	77 (11.7)	
COPD	18 (3.20)	3 (3.09)	21 (3.18)	
CHD	13 (2.31)	2 (2.06)	15 (2.27)	
Preoperative laboratory test				
ALB (g/L)	43.23±2.48	40.36±3.48	42.85±2.84	
Hb (g/L)	134.33±15.28	133.00±12.87	134.13±14.95	
CRP (mg/L)	4.11±3.44	5.01±5.02	4.24±3.73	
ESR (mm/h)	23.65±16.84	28.82±18.65	24.40±17.19	

Values are shown as n (%) or mean \pm standard deviation. ALB: albumin; BMI: body mass index; CHD: coronary heart disease; COPD: chronic obstructive pulmonary disease; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; Hb: hemoglobin.

Supplementary Table 2. Baseline characteristics of patients who underwent routine primary TKA from January to August 2020.

Baseline characteristic	No albumin (n=88)		
Demographic characteristic			

Age (year)	64.32±10.88
Female	63 (71.6)
BMI (kg/m²)	26.11±3.92
Diagnosis	
Primary osteoarthritis	81 (92.0)
Inflammatory arthritis	7 (7.95)
Comorbidity	
Hypertension	37 (42.0)
Diabetes	10 (11.4)
COPD	5 (5.68)
CHD	5 (5.67)
Preoperative waiting time (days)	39.05±22.78

Values are shown as n (%) or mean \pm standard deviation. BMI: body mass index; COPD: chronic obstructive pulmonary disease; CHD: coronary heart disease.

Supplementary Table 3. Logistic regression analyses of preoperative albumin level and HAS use after primary TKA.

Model	Risk of postoperative albumin use			
-	Risk ratio (95% confidence interval)	P		
Crude model	0.720 (0.665-0.778)	<0.001		
Model 1	0.772 (0.665-0.784)	<0.001		
Model 2	0.722 (0.664-0.785)	<0.001		
Model 3	0.725 (0.666-0.789)	<0.001		


Model 1: adjusted for age, sex, body mass index and diagnosis.

Model 2: adjusted as in model 1 + hypertension, type 2 diabetes, chronic obstructive pulmonary disease, and coronary heart disease.

Model 3: adjusted as in model 2 + preoperative hemoglobin, C-reactive protein, and erythrocyte sedimentation rate.

Variables	Pre-op ESR	Pre-op CRP	Pre-op Hb	CHD	COPD	Diabetes	Variables
Pre-op ALB	1	0.285	-0.260	-0.020	0.007	-0.009	Pre-op ESR
Sex	0.000	1	-0.043	-0.089	-0.034	-0.045	Pre-op CRP
Age	0.000	-0.042	1	-0.046	-0.037	-0.118	Pre-op Hb
ВМІ	0.019	0.000	-0.016	1	0.030	0.040	CHD
Diagnosis*	-0.144	-0.079	-0.235	-0.223	1	-0.012	COPD
Hypertension	0.074	0.067	0.247	0.126	-0.046	1	Diabetes
Diabetes	0.086	0.090	0.103	0.051	-0.044	0.121	
COPD	-0.037	-0.037	0.029	0.021	-0.016	0.051	
CHD	0.001	0.001	0.065	0.004	-0.042	0.093	
Pre-op Hb	0.096	-0.375	-0.050	0.245	-0.221	0.010	
Pre-op CRP	-0.154	0.058	-0.066	0.092	0.240	-0.002	
Pre-op ESR	-0.129	0.240	0.073	-0.074	0.188	0.071	
Variables	Pre-op ALB	Sex	Age	вмі	Diagnosis	Hypertension	

Supplementary Figure 1: Spearman's rank correlations between covariates included in the logistic regression analyzes. ALB: Albumin; BMI: Body mass index; CHD: Coronary heart disease; COPD: Chronic obstructive pulmonary disease; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; Hb: Hemoglobin; Pre-op: Preoperative. Including osteoarthritis and inflammatory arthritis.



Supplementary Figure 2: Dose-response relationship between Pre-op serum ALB level and risk of HAS use. ALB: Albumin; HAS: Human albumin solution; Pre-op: Preoperative.